Cash Position Grows to $25.9 Million KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead ADHD asset, CTx-1301, to market,” said Cingulate CEO Shane J. Schaffer. “We continue to engage constructively with the FDA on our new drug application while advancing commercial readiness and manufacturing capabilities, and believe our current resources provide an extended cash runway into 2027.” Strengthened Balance Sheet Cingulate...

Company re-affirms 2026 guidance and provides expectations for medium-term outlook for 2027 to 2029 MILWAUKEE, May 14, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, will host its Investor Day today beginning at 9:00 a.m. ET. The event will feature presentations from Fiserv senior leadership and will focus on the company’s strategy and execution priorities, as well as outline its medium-term financial outlook. At the event, the company will focus on how disciplined execution of its One Fiserv action plan, with opportunities at the intersection of its Merchant and Financial Solutions businesses, are expected to drive a constant compounder financial profile. “Our businesses play a critical role across the financial ecosystem,” said Mike Lyons,...

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program in May 2026 Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene...

Company Introduces Condor, Merlin’s first product, bringing Merlin Pilot to large, multi-crew aircraft for civil and defense missions BOSTON, May 14, 2026 (GLOBE NEWSWIRE) — Merlin, Inc. (Nasdaq: MRLN), an aerospace and defense technology company building the operating system of record for autonomous flight, today announced operating and financial results for its first quarter ended March 31, 2026. This was the Company’s first quarterly report of operations as a public company following the close of its business combination with Inflection Point Acquisition Corp. IV on March 16, 2026. Business HighlightsAutomated takeoffs. On April 11 and April 21, Merlin executed its first fully automated takeoffs on fixed wing aircraft, one in the United States and one in New Zealand. Certification progression. Merlin’s civil certification...

OMAHA, NE, May 14, 2026 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2026. Highlights for the first quarter ended March 31, 2026 include:Total revenue was $25.3 million, an increase of 59% compared to the first quarter of 2025.   Wholesale revenue was $14.1 million, or 56% of total revenue, an increase of 166% compared to the first quarter of 2025. Online revenue was $11.2 million, or 44% of total revenue, an increase of 6% compared to the first quarter of 2025. Gross margin was 37.6% compared to 43.1% during the first quarter of 2025, with the decline in gross margin primarily attributable to the acquisition of Irwin, which historically...

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform TORONTO, May 14, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis. “The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial and pharmaceutical pipeline. We delivered record quarterly revenue, gross profit and gross margins, driven by sustained growth in Canada,...

‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., May 14, 2026 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the first quarter ended March 31, 2026 and provided an update on its business. Recent Corporate Highlights:CorMedix announces $127.4 million of net revenue for the first quarter of 2026, reflecting strong first quarter execution and positive underlying demand trends. The Company also recognized net income of $38.6 million and adjusted EBITDA of $70.0 million.(1) Basic and fully diluted EPS were $0.48 and $0.43 per share, respectively, for the quarter.DefenCath®...

Delivered quarterly net revenue of $13.7 million for Q1 2026 (11% increase from Q1 2025).Adjusted EBITDA1 loss of $0.6 million for Q1 2026 (compared to positive $0.7 million in Q1 2025) driven by Cascadia pre-revenue scale-up and B.C. strike impact.#1 premium licensed producer in Canada with 7.5% of the market share.2Cascadia facility in full production with quality and yields meeting or exceeding internal expectations. First commercial sales expected by mid-2026.In April, expanded the total addressable market for the Company’s largest and most awarded brand with the 1964 Supply CoTM launch in the U.K.VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and...

Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the three months ended March 31, 2026. “Our first quarter results reflect continued progress as we execute on the foundation established in 2025,” said Eric Hines, Chief Executive Officer of Milestone Scientific. “We delivered meaningful improvements in operating efficiency, reducing expenses by more than 30% and significantly narrowing our operating loss, while maintaining a relatively stable revenue...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the first quarter ended March 31, 2026. “We delivered a strong start to the year that tracks both our operational and expansion plans,” said Jean Martineau, President & CEO. “Operations maintained strong ore supply momentum, which, coupled with higher recoveries, resulted in record first-quarter production volumes. Supported by the higher gold pricing, this operational outperformance translated into record earnings per share and operating cash flow. With initial production from two new plants set to come online this year, including the first from Senegal later this quarter, we remain firmly on track to deliver stronger production in the second half of...